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Abstract 
Review on t(9;14)(p24;q12), with data on clinics, 
and the genes involved. 
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Clinics and pathology 
Disease 
Acute lymphoblastic leukemia (ALL). 
Epidemiology 
Only 1 case to date, a 12 year-old female patient with 
high-risk B-lineage ALL (Roberts et al., 2012). 
Genes involved and 
proteins 
Note 
There was a IKZF1 deletion and p.Leu117fs (Frame 
shift) mutation. 
JAK2 (janus kinase 2) 
Location 9p24.1 
Protein 
1132 amino acids (aa); 130,7 kDa; JAK2 contains an 
Interaction with cytokine/interferon/growth 
hormone receptors region (aa 1-239), a FERM 
domain: (aa 37-380), a central Src homology 2 
(SH2) domain (aa 401-482), and two C-terminal 
domains: a tyrosine kinase domain JH1 (also termed 
PTK or TyrKc domain (aa 545-809)), and a tyrosine 
kinase-like domain JH2 (also termed STYKc (aa 
849-1124)). JAK Homology domains are the 
following: JH7 aa 25-137; JH6: aa 144-284; JH5: aa 
288-309; JH4: aa 322-440; JH3: aa 451-538; JH2: aa 
543-824; JH1: aa 836-1123. 
JAK2 is a member of the Janus kinase (JAKs) family 
of non-receptor protein tyrosine kinases ( JAK1, 
JAK2, JAK3, TYK2) .Janus kinases are protein 
tyrosine kinases of the non-receptor type that 
associates with the intracellular domains of cytokine 
receptors including the receptors for interleukins, 
interferons, growth hormone, erythropoietin, and 
leptin. Mediates signaling transduction. Janus 
kinases are constitutively bound to the cytoplasmic 
region of cytokine receptors. Binding of cytokines 
induces cytokine receptor dimerization, facilitating 
trans-phosphorylation of the associated JAKs and 
JAK/STAT signaling. Erythropoietin receptor 
(EPOR) and growth hormone receptor (GHR) bind 
JAK2 exclusively.  
JAK2 is frequently mutated in myeloproliferative 
disorders. JAK2-V617F mutation occurs at the stem 
cell level and is present in hematopoietic stem cell 
progenitors (Strehl et al., 2006; Gangat and Tefferi, 
2008; Hubbard, 2017). 
STRN3 (striatin 3) 
Location 14q12 
Protein 
797 amino acids (aa), contains caveolin-binding and 
calmodulin-binding regions in the N-term (aa 71-79 
and 166-183 respectively), a coiled-coil domain (aa 
77-136, which allow homo- and hetero-
oligomerization), and 6 WD repeats (from aa 478 to 
aa 796; WD-repeat domain enables proteins to 
establish multiple protein-protein interactions). 
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STRN3 is a member of striatin family ( STRN, 
STRN3, STRN4) which function as scaffold in 
different signal transduction pathways STRN and 
STRN3 are the constituents of a multiprotein 
assembly called striatin-interacting phosphatase and 
kinase (STRIPAK). STRIPAK are regulators of cell 
cycle, differentiation, metabolism, immune 
regulation, Golgi assembly, cell polarity, cell 
migration, etc. STRN3 protects cells from oxidative 
stress. SG2NA is involved in maintaining ER 
homeostasis. Downregulation of SG2NA reduces the 
level of CCND1 (cyclin D1) and retains a population 
of cells in the G1 phase, and its overexpression 
extends G2 (Jain et al., 2017; Pandey et al., 2018). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
STRN3 exon 9 was fused to JAK2 exon 17. 
Fusion protein 
Description 
835 amino acids. The N-term striatin domain was 
fused to the pseudo kinase domain and C-term Tyr 
kinase domain). Sequence junction: 
.ARAEEV_LQER.... 
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